EchoIQ Limited (AU:EIQ) has released an update.
EchoIQ Limited has announced the initiation of a clinical study in partnership with St. Vincent’s Institute of Medical Research to test their innovative AI algorithm designed to improve the detection of heart failure. This new technology has the potential to enhance patient care by enabling earlier treatment and could have substantial economic benefits in the heart failure healthcare market worth $60 billion annually. EchoIQ is also focused on obtaining FDA clearance and insurance reimbursement codes to maximize the solution’s commercial viability.
For further insights into AU:EIQ stock, check out TipRanks’ Stock Analysis page.
